OMER vs DNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 15, 2026

OMER

44.1
AI Score
VS
DNA Wins

DNA

49.5
AI Score

Investment Advisor Scores

OMER

44score
Recommendation
HOLD

DNA

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric OMER DNA Winner
Revenue 38.42M 39.63M DNA
Net Income 69.29M -129.30M OMER
Net Margin 180.3% -326.3% OMER
Operating Income -17.35M -129.92M OMER
ROE -134.9% -30.8% DNA
ROA 24.2% -13.1% OMER
Total Assets 286.83M 990.05M DNA
Cash 1.99M 84.53M DNA
Current Ratio 1.95 4.57 DNA
Free Cash Flow -10.40M -95.51M OMER

Relative Price Performance (Last 90 Days)

OMER 1M: +61.5% · 3M: +64.6% DNA 1M: -6.1% · 3M: -17.0%

Current Technical Phase

OMER

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (18.9% over 20 days), RSI 73

RSI (14): 72.7 · Price: $18.22

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.2 · Price: $7.23

Fundamentals Snapshot

Metric OMER DNA
Market Cap
Forward P/E 15.9 -2.5
Trailing P/E 11.7
Revenue (TTM)
Revenue Growth 0.1% -0.5%
Gross Margin 0.4% 0.7%
Operating Margin 0.0% -2.8%
EPS 1.65 -5.93
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, DNA is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.